$VKTX Q2 2026 earnings: Viking advances its obesity trials, but its cash shrinks fast
Viking Therapeutics, a clinical-stage developer of obesity drugs, slowed its quarterly spending while its cash balance kept shrinking at the same pace. Operating expenses fell 19% from the first quarter to $133 million as drug manufacturing bills eased, and chief executive Brian Lian kept all four obesity clinical trials on schedule. Even so, cash and short-term investments dropped by $101 million to $502 million, leaving five quarters of funding at the current pace by our math.
โข Cash and short-term investments: $๐๐๐๐ (down $101M from last quarter)
โข Research and development expenses: $๐๐๐.๐๐ (down 23% from last quarter)
โข Net loss per share: $๐.๐๐ ($0.58 a year ago)
โข Cash runway outlook: ๐๐ง๐๐ก๐๐ง๐ ๐๐ (management projects cash into 2028)
โ๏ธ ๐๐๐ซ๐๐ข๐๐ญ: โช Neutral
The story is unchanged because lower quarterly expenses did not slow the actual cash drain. Management eased one cost concern by noting that the upcoming Phase 3 trials for its obesity pill will be roughly 75% smaller than its injectable trials. One caution: Lian revealed that the Phase 1 maintenance study compressed the initial dose ramp-up to reach higher doses faster, which could inflate stomach side effects when data arrives this quarter.
The question now is whether quarterly cash burn can drop enough to fund the company into 2028 as finance chief Greg Zante plans. One view is that peak spending on the injectable Phase 3 trials has passed; the other is that starting two oral Phase 3 trials and paying supplier commitments will force a capital raise before the 2027 Phase 3 readouts. The cash flow statement in the upcoming quarterly filing and fourth-quarter spending will settle it.
Full article with charts - link in bio
๐ ๐๐ฎ๐ฅ๐ฅ ๐๐๐ฌ๐
๐ข ๐๐ซ๐ข๐๐ฅ ๐๐ฉ๐๐ง๐๐ข๐ง๐ ๐๐ซ๐จ๐ฉ๐ฉ๐๐ ๐๐ง๐ ๐๐ซ๐๐ฅ ๐๐ญ๐ฎ๐๐ข๐๐ฌ ๐๐จ๐ฌ๐ญ ๐๐๐ฌ๐ฌ
Viking is a biotechnology company developing treatments for obesity, so it has no product sales and its main financial measure is research spending. Finance chief Greg Zante said on the call regarding cash burn, "I think this is really the heaviest usage period." Total operating expenses fell 19.2% from the first quarter to $132.6 million as drug manufacturing bills eased.
The company also gave new detail on the upcoming Phase 3 trials for the pill version of VK2735, its lead weight-loss drug. Chief executive Brian Lian said the two oral studies will be "75% smaller than the VANQUISH study", the 5,500-patient injectable program. Lian added, "It's quite a bit smaller, so the expense will be quite a bit lower as a result."
What to watch: research and development expenses in the third and fourth quarters. A further decline even as the oral Phase 3 trials start in the fourth quarter would confirm that quarterly spending has peaked.
๐ข ๐ ๐จ๐ฎ๐ซ ๐๐๐๐ฌ๐ข๐ญ๐ฒ ๐๐ฅ๐ข๐ง๐ข๐๐๐ฅ ๐๐ซ๐จ๐ ๐ซ๐๐ฆ๐ฌ ๐๐๐ฏ๐๐ง๐๐ ๐จ๐ง ๐๐๐ก๐๐๐ฎ๐ฅ๐
The drug developer wants to offer patients multiple ways to lose weight and keep it off. Its main drug, VK2735, mimics two gut hormones (GLP-1 and GIP) that regulate appetite and blood sugar. During the quarter, Viking switched patients in its two Phase 3 VANQUISH injectable trials from vials and syringes to auto-injector pens. Lian noted regarding the switch, "Your clinic visits dropped from 4 per month to 1 per month."
Fewer clinic visits make it easier for the 5,500 enrolled patients to stay in the 78-week studies. Meanwhile, the company started a Phase 1 human trial of VK3019, a new obesity drug targeting amylin and calcitonin receptors that control hunger. It also remained on schedule to report Phase 1 maintenance dosing results in the third quarter and start Phase 3 oral trials in the fourth quarter.
What to watch: the Phase 1 maintenance study results later this quarter. Retaining 75% to 80% of initial weight loss on monthly or every-other-week shots would give the company regimens to test in the Phase 3 extension trials.
๐ป ๐๐๐๐ซ ๐๐๐ฌ๐
๐ด๐ด ๐๐๐ฌ๐ก ๐๐ฎ๐ซ๐ง ๐๐ฎ๐ญ๐ฉ๐๐๐๐ฌ ๐ญ๐ก๐ ๐๐๐๐ ๐๐ฎ๐ง๐ฐ๐๐ฒ ๐๐๐ซ๐ ๐๐ญ
Zante told analysts on the call, "And our guidance remains intact that we have cash into 2028." That claim clashes with the current pace of cash consumption. Even though operating expenses dropped from the first quarter, Viking's cash and short-term investments still fell by $101.3 million in the second quarter, matching the $102.8 million drop in the first quarter.
โข Ending cash and short-term investments: $501.7 million, down from $705.7 million at year-end 2025
โข Second-quarter cash decline: $101.3 million by our math
โข Runway at current pace: 5.0 quarters by our math, ending in the third quarter of 2027
โข Maximum burn to reach 2028: $83.6 million per quarter over the next six quarters by our math
To stretch $501.7 million across the six quarters to reach 2028, quarterly cash use must fall by 17.5% by our math. Yet the company is about to start two Phase 3 oral trials and owes manufacturing prepayments to its supplier CordenPharma between 2026 and 2028.
What to watch: the operating cash flow line in the upcoming second-quarter 10-Q filing. An operating cash outflow near $100 million would show that the funding gap ahead of the 2027 Phase 3 readouts remains open.
๐ด ๐๐จ๐ฆ๐ฉ๐ซ๐๐ฌ๐ฌ๐๐ ๐๐จ๐ฌ๐ข๐ง๐ ๐๐จ๐ฎ๐ฅ๐ ๐๐ฅ๐จ๐ฎ๐ ๐ญ๐ก๐ ๐๐ก๐ข๐ซ๐-๐๐ฎ๐๐ซ๐ญ๐๐ซ ๐๐๐๐๐จ๐ฎ๐ญ
In the third quarter, the San Diego company will report data from its 180-patient Phase 1 maintenance study, which tests whether patients can switch from weekly shots of VK2735 to every-other-week or monthly shots. On the call, Lian revealed a design trade-off in the initial 21-week weight-loss phase: "We compressed the titration blocks in that first 21-week treatment period."
Titration is the gradual step-up in drug dose over time to help patients avoid nausea and vomiting. The study also pushed doses up to 20 milligrams and 22.5 milligrams, higher than the 15-milligram top dose in Phase 2. Stepping up doses faster to reach higher levels risks raising stomach side effects during the first 21 weeks, and Lian noted that a period-by-period side-effect breakdown might not be ready for the initial release.
What to watch: whether the third-quarter release separates side-effect rates between the 21-week ramp-up and the 12-week maintenance phase. Combined numbers with high nausea rates would make it hard to judge if monthly maintenance dosing is well tolerated.
๐ด ๐๐ข๐ฌ๐ค๐ฌ ๐ญ๐ก๐ข๐ฌ ๐ช๐ฎ๐๐ซ๐ญ๐๐ซ ๐๐ข๐๐ง'๐ญ ๏ฟฝ๏ฟฝ๐ง๐ฌ๐ฐ๐๐ซ
Four standing concerns from prior quarters received no new data or commentary in the second-quarter release and conference call.
โข Ligand Pharmaceuticals license dispute: neither the release nor the call mentioned Ligand's April notice purporting to terminate the license for liver drug VK2809 and rare-disease drug VK0214; the 10-Q legal footnote will show its status.
โข Cardiovascular outcomes trial: management still has not outlined a heart-outcomes study for VK2735, which rival obesity drugmakers use to secure insurance coverage; any trial announcement would clarify long-term costs.
โข Oral drug competition: oral VK2735 starts Phase 3 in the fourth quarter against rival pills already on the market; Phase 3 dose selection in the fourth quarter will show how Viking positions the tablet.
โข VANQUISH-2 patient count: the diabetes obesity trial closed at roughly 1,000 patients against an earlier 1,100 target; baseline demographics at upcoming medical conferences will show the final trial size.
๐ ๐๐ญ๐ก๐๐ซ ๐๐ก๐๐ฆ๐๐ฌ
๐๐จ๐ฆ๐ฆ๐๐ซ๐๐ข๐๐ฅ ๐๐ง๐ ๐๐๐๐ข๐๐๐ฅ ๐๐๐๐๐๐ซ๐ฌ๐ก๐ข๐ฉ ๐๐ข๐ซ๐๐ฌ ๐๐จ๐ง๐ญ๐ข๐ง๐ฎ๐
As its obesity drugs move through late-stage testing, the biotech group is hiring staff for regulatory filings and sales. In the second quarter, Viking appointed Hubert Chen as chief medical officer to oversee clinical trials and regulatory affairs, and after the quarter ended it named former GoodRx executive Dorothy Gemmell to its board. Hiring and consulting drove general and administrative expenses up 16.8% from a year ago to $16.8 million.
โ โข โ โข โ
๐ฒ ๐๐ญ๐ก๐๐ซ ๐๐๐๐ฌ
๐๐๐๐จ๐ฎ๐ง๐ญ๐ฌ ๐ฉ๐๐ฒ๐๐๐ฅ๐ ๐๐ง๐ ๐๐๐๐ซ๐ฎ๐๐ ๐ฅ๐ข๐๐๐ข๐ฅ๐ข๐ญ๐ข๐๐ฌ (๐๐๐๐): $๐๐๐.๐ ๐ฆ๐ข๐ฅ๐ฅ๐ข๐จ๐ง โ accelerating
Unpaid bills and accrued clinical expenses rose to $109.5 million by our math ($69.0 million in accounts payable plus $40.5 million in accrued liabilities), up 43.1% from $76.5 million at the end of 2025. Delaying cash payments to vendors cushioned the second-quarter cash balance, meaning those bills will draw down cash in future quarters.
๐๐ซ๐๐ฉ๐๐ข๐ ๐๐ฅ๐ข๐ง๐ข๐๐๐ฅ ๐ญ๐ซ๐ข๐๐ฅ ๐๐จ๐ฌ๐ญ๐ฌ (๐๐๐๐): $๐๐.๐ ๐ฆ๐ข๐ฅ๐ฅ๐ข๐จ๐ง โ accelerating
Upfront payments for clinical trials and early-stage studies more than tripled from the first quarter, rising 272.0% from $4.0 million to $15.0 million (and up from $8.1 million at year-end 2025). The jump reflects upfront deposits for the new VK3019 Phase 1 trial and preparations for the fourth-quarter oral Phase 3 studies.
๐๐๐ข๐ ๐ก๐ญ๐๐-๐๐ฏ๐๐ซ๐๐ ๐ ๐๐ข๐ฅ๐ฎ๐ญ๐๐ ๐ฌ๐ก๐๐ซ๐๐ฌ (๐๐๐๐): ๐๐๐.๐ ๐ฆ๐ข๐ฅ๐ฅ๐ข๐จ๐ง โ accelerating
The average share count rose 3.7% from 112.1 million a year ago, and total issued shares reached 116.7 million at quarter end (up from 114.8 million at year-end 2025). Additional paid-in capital increased by $34.7 million from the first quarter by our math, driven by employee stock compensation and ongoing share issuances.
โ โข โ โข โ
๐ฎ ๐๐ฎ๐ข๐๐๐ง๐๐
๐๐๐ฌ๐ก ๐๐ฎ๐ง๐ฐ๐๐ฒ ๐๐ง๐ ๐๐ฎ๐๐ซ๐ญ๐๐ซ๐ฅ๐ฒ ๐๐๐ฌ๐ก ๐๐ฌ๐๐ ๐: ๐๐๐ฌ๐ก ๐ข๐ง๐ญ๐จ ๐๐๐๐ (๐ญ๐๐ฉ๐๐ซ๐ข๐ง๐ ๐๐ซ๐จ๐ฆ ๐๐) โ decelerating
๐ unchanged from Cash into 2028; Q2 spend at or below Q1 ($114M cash use / $164.1M OpEx)
Unchanged. Zante reiterated that the $502 million cash balance will fund the company into 2028 and that quarterly cash burn will taper from current levels. By our math, reaching the start of 2028 (six quarters away) requires average quarterly cash burn to drop by 17.5%, from $101.3 million in the second quarter to $83.6 million or less.
๐๐๐๐๐๐ ๐๐ก๐๐ฌ๐ ๐ ๐๐๐ข๐ง๐ญ๐๐ง๐๐ง๐๐ ๐๐ญ๐ฎ๐๐ฒ ๐๐๐๐๐จ๐ฎ๐ญ: ๐๐๐๐ ๐๐๐ญ๐ ๐ซ๐๐ฅ๐๐๐ฌ๐ โ stable
๐ unchanged from 3Q26 data release
Unchanged. The clinical-stage group still plans to report results from the subcutaneous maintenance dosing study later in the third quarter of 2026. The oral maintenance cohorts of this study remain scheduled for completion in the first half of 2027.
๐๐ซ๐๐ฅ ๐๐๐๐๐๐ ๐๐ก๐๐ฌ๐ ๐ ๐๐ซ๐ข๐๐ฅ ๐๐ง๐ข๐ญ๐ข๐๐ญ๐ข๐จ๐ง: ๐๐๐๐ ๐ข๐ง๐ข๐ญ๐ข๐๐ญ๐ข๐จ๐ง โ stable
๐ unchanged from 4Q26 initiation
Unchanged. Management kept its target to start two Phase 3 obesity trials for the daily tablet version of VK2735 in the fourth quarter of 2026, following a one-quarter slip from the third quarter to the fourth quarter announced earlier this year.
โ โข โ โข โ
โ ๐๐๐ฒ ๐๐ฎ๐๐ฌ๐ญ๐ข๐จ๐ง๐ฌ
๐๐ก๐๐ญ ๐ฐ๐๐ฌ ๐จ๐ฉ๐๐ซ๐๐ญ๐ข๐ง๐ ๐๐๐ฌ๐ก ๐๐ฎ๐ซ๐ง ๐ข๐ง ๐ญ๐ก๐ ๐ฌ๐๐๐จ๐ง๐ ๐ช๐ฎ๐๐ซ๐ญ๐๐ซ?
The earnings release omits the cash flow statement. Investors need the 10-Q filing to see whether operating cash outflow stayed below the first quarter's $114.0 million or if equity sales offset a larger burn.
๐๐ข๐ฅ๐ฅ ๐ญ๐ก๐ ๐ฆ๐๐ข๐ง๐ญ๐๐ง๐๐ง๐๐ ๐ซ๐๐๐๐จ๐ฎ๐ญ ๐ฌ๐๐ฉ๐๐ซ๐๐ญ๐ ๐ซ๐๐ฆ๐ฉ-๐ฎ๐ฉ ๐ฌ๐ข๐๐ ๐๐๐๐๐๐ญ๐ฌ?
Viking compressed the dose ramp-up in the 21-week induction phase and tested higher doses up to 22.5 milligrams. If the initial data release blends induction and maintenance side effects, high early nausea could obscure the maintenance profile.
๐๐ก๐๐ญ ๐ข๏ฟฝ๏ฟฝ๏ฟฝ ๐ญ๐ก๐ ๐ฌ๐ญ๐๐ญ๐ฎ๐ฌ ๐จ๐ ๐ญ๐ก๐ ๐๐ข๐ ๐๐ง๐ ๐ฅ๐ข๐๐๐ง๐ฌ๐ ๐๐ข๐ฌ๐ฉ๐ฎ๐ญ๐?
Ligand notified Viking in April that it was terminating the license for liver drug VK2809 and rare-disease drug VK0214. Management did not mention the dispute on the call, leaving its legal and financial impact unclear.
๐๐ก๐๐ง ๐๐จ ๐๐จ๐ซ๐๐๐ง๐๐ก๐๐ซ๐ฆ๐ ๐ฆ๐๐ง๐ฎ๐๐๐๐ญ๐ฎ๐ซ๐ข๐ง๐ ๐ฉ๐ซ๐๐ฉ๐๐ฒ๐ฆ๐๐ง๐ญ๐ฌ ๐๐๐ ๐ข๐ง?
Viking agreed to make multi-year capacity prepayments to CordenPharma between 2026 and 2028. How those scheduled cash outflows fit inside a tapering quarterly cash burn projection remains unexplained.
๐จ Anthropic just showed a 24-minute workshop on how to actually do prompts for Claude.
Taught by the people who built it.
Free. No registration. No paywall.
I've seen $300 courses that don't cover what they teach in the first 8 minutes.
Watch it and bookmark it now.
A Persian scholar finished a single math book in 9th century Baghdad that quietly became the foundation for every line of code running on Earth today.
I started reading about him at midnight and could not believe how many things in my daily life trace back to one man.
His name was Muhammad ibn Musa al-Khwarizmi. The book is called The Compendious Book on Calculation by Completion and Balancing.
Every time you say the word algebra, you are saying his book title. Every time someone says the word algorithm, they are saying his name. Both English words come from him. Both are Latin transliterations of Arabic and of his own identity. The man did not just contribute to mathematics. He named it.
Here is the part almost nobody tells you.
Al-Khwarizmi was born around 780 CE in Khwarazm, in what is now Uzbekistan. He moved to Baghdad and worked at a research institution called the House of Wisdom, which during the Islamic Golden Age was the single most important center of learning on the planet. The caliph al-Mamun hired the best mathematicians, astronomers, and philosophers from across three continents and put them in one building with one job. Translate, study, and produce new knowledge.
Al-Khwarizmi finished his book on algebra around 820 CE. The Arabic title contained the word al-jabr, which referred to one of the two operations he used to solve equations. When the book was translated into Latin in the 12th century, the Latin world did not have a word for what he had built. So they kept his Arabic word. Al-jabr became algebra. The discipline was named after a single Arabic word in the title of a single book by a single man.
The deeper insight is what he actually changed about how humans think.
Before al-Khwarizmi, mathematical problems were solved geometrically. You drew shapes. You measured them. You compared areas. The Greeks had built an entire mathematical tradition on visual proofs and physical constructions. It was beautiful and limited. You could not solve a problem you could not draw.
Al-Khwarizmi did something nobody had done before him at this scale. He said you could solve any problem using abstract symbols and rules. You did not need a shape. You needed a procedure. You moved terms across the equation. You cancelled like terms on both sides. You isolated the unknown. He invented the idea that mathematics is a manipulation of symbols according to rules, not a study of physical figures.
That single shift made everything that came afterward possible. Calculus. Differential equations. Linear algebra. Quantum mechanics. None of it works if math is locked inside geometry. He pulled it out.
The second thing he did is the one that changed how the world counted forever. He took the Hindu numeral system from Indian mathematics, refined it, and wrote a book introducing it to the Arab world. That system included the concept of zero as a placeholder, and a positional notation where the value of a digit depends on its location. Roman numerals could not do complex calculation. Hindu-Arabic numerals could.
When his book on numerals was translated into Latin as Algoritmi de numero Indorum, the word Algoritmi was just the Latin spelling of his own name. Europeans started calling the new method "doing algorism," then "running an algorithm." The word for the most important concept in computer science is literally his name in Latin.
The third thing he did is the part that should haunt anyone who works in tech.
His method of solving problems was systematic. Step one, do this. Step two, check that. Step three, if condition A, then do X, otherwise do Y. He wrote down procedures that could be followed by anyone, anywhere, who knew how to read. The procedure did not depend on intuition or genius. It worked because the steps worked.
That is exactly what an algorithm is. A finite, deterministic procedure for solving a problem. He did not just give us the word. He gave us the entire concept of programming a thousand years before there was anything to program.
When Alan Turing built the first abstract model of computation in 1936, when John von Neumann designed the first stored-program computer in 1945, when every engineer at Google, OpenAI, Anthropic, and DeepMind writes code in 2026, they are working in a paradigm that started with one man in Baghdad twelve centuries ago.
The strangest part is what happens when you walk into any tech office in San Francisco or Bangalore or Lahore today. Engineers say the words algebra and algorithm hundreds of times a day. They do not know whose name they are saying. Almost nobody can spell al-Khwarizmi correctly on the first try.
His original Arabic manuscript is preserved at Oxford. His book on Hindu numerals survives only in Latin translation. The Latin version was the textbook that taught medieval Europe how to count.
The man who built the foundation of the AI revolution did not live to see a calculator. He died around 850 CE, a thousand years before the first electric current was sent through a wire. The civilization he built mathematics for collapsed. The library he wrote in burned. His own grave is unmarked.
But every algorithm running on every machine on Earth right now still answers to his name.
@MarriottBonvoy@Marriott@MBonvoyAssist terrible experience at Fairfield Inn Savannah I-95 South. The heat in the room was not working, mediocre breakfast...
$QQQ $SPY
Maybe we break that trend line, orโฆ
What if the biggest part of the rally was about to start?
That would be crazy right? It would need stimulus or somethin to do that right?
Is there any Monetary easing or any major interest rate policy or any major bond buying or tappering of bond selling on the horizon at all? Is any catalyst like that near this chart that u can think of? Any major change in the last several years to money happening anytime soon?
6 of the Top 10 Biotech M&A Deals in 2024 were public companies,
At least one biotech specialist fund had a stake in each with an avg of 6 specialists owning 25.8%,
Top Specialist Funds for Public M&A Deals so far this year:
RA Capital - 3 deals (9.9% of $INBX, 6.1% $CBAY, 7.5% $ALPN)
Perceptive Advisors - 3 deals (9% $INBX, 3.6% $CBAY, 6.5% $FUSN)
Cormorant - 3 deals (17.8% $AMAM, 3.4% $CBAY, 3.9% $ALPN)
H/T @timopler@stifel
$XBI $IBB